| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.081 | 0.008 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.009 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.075 | 0.01 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | serdemetan:SCH-529074 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |